NYSE:EBS Emergent BioSolutions - EBS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.79 -0.38 (-4.65%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.77▼$8.2350-Day Range$7.79▼$16.2952-Week Range$7.77▼$45.14Volume1.05 million shsAverage Volume1.56 million shsMarket Capitalization$390.59 millionP/E RatioN/ADividend YieldN/APrice Target$31.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Emergent BioSolutions MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside300.5% Upside$31.20 Price TargetShort InterestBearish13.65% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment-0.08Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.22) to $1.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector277th out of 986 stocksPharmaceutical Preparations Industry118th out of 477 stocks 3.0 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.20, Emergent BioSolutions has a forecasted upside of 300.5% from its current price of $7.79.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.65% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Emergent BioSolutions has recently decreased by 1.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 1.6 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Emergent BioSolutions this week, compared to 3 articles on an average week.Search Interest52 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 373% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.Percentage Held by Insiders11.10% of the stock of Emergent BioSolutions is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.44% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.22) to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Emergent BioSolutions (NYSE:EBS) StockEmergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.Read More Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Stock News HeadlinesMarch 21, 2023 | americanbankingnews.comJPMorgan Chase & Co. Reiterates "Underweight" Rating for Emergent BioSolutions (NYSE:EBS)March 20, 2023 | benzinga.comEmergent BioSolutions Stock (NYSE:EBS), Analyst Ratings, Price Targets, PredictionsMarch 23, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. March 20, 2023 | nasdaq.comJP Morgan Downgrades Emergent Biosolutions (EBS)March 18, 2023 | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Research Coverage Started at StockNews.comMarch 16, 2023 | americanbankingnews.comAnalysts Offer Predictions for Emergent BioSolutions Inc.'s Q1 2023 Earnings (NYSE:EBS)March 15, 2023 | americanbankingnews.comZacks Research Comments on Emergent BioSolutions Inc.'s Q3 2023 Earnings (NYSE:EBS)March 10, 2023 | finance.yahoo.comEmergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Call TranscriptMarch 23, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. March 1, 2023 | msn.comEmergent's (EBS) Q4 Earnings Miss, Sales Beat EstimatesMarch 1, 2023 | finance.yahoo.comEmergent BioSolutions Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsFebruary 28, 2023 | finance.yahoo.comQ4 2022 Emergent BioSolutions Inc Earnings CallFebruary 28, 2023 | finance.yahoo.comWall Street Analysts Believe Emergent Biosolutions (EBS) Could Rally 134.29%: Here's is How to TradeFebruary 27, 2023 | finance.yahoo.comEmergent BioSolutions Reports Financial Results for Fourth Quarter 2022February 27, 2023 | finance.yahoo.comEmergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue EstimatesFebruary 24, 2023 | seekingalpha.comEmergent Biosolutions Q4 2022 Earnings PreviewFebruary 24, 2023 | msn.comEarnings Outlook For Emergent BioSolutionsFebruary 23, 2023 | finance.yahoo.comFulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseFebruary 21, 2023 | seekingalpha.comEmergent BioSolutions: Positive NARCAN FDA Panel, Divesting Travel Health, Raising Rating To BuyFebruary 16, 2023 | finance.yahoo.comEmergent’s stock jumps after FDA panel favors over-the-counter sales of NarcanFebruary 15, 2023 | benzinga.comEmergent BioSolutions Reports FDA Advisory Committees' Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter UseFebruary 15, 2023 | finance.yahoo.comUPDATE 2-U.S. FDA panel backs OTC opioid overdose drug, proposes label changesFebruary 15, 2023 | finance.yahoo.comFDA panel says opioid antidote Narcan should be available over the counterFebruary 15, 2023 | finance.yahoo.comEmergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter UseFebruary 15, 2023 | finance.yahoo.comEmergent BioSolutions scores FDA advisory panel’s vote to sell opioid overdose drug Narcan without prescriptionFebruary 15, 2023 | marketwatch.comEmergent BioSolutions Shares Rise on Travel-Health Sale >EBSFebruary 15, 2023 | msn.comFDA Advisers to Consider Emergent’s Nonprescription Overdose AntidoteSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Company Calendar Last Earnings2/27/2023Today3/23/2023Next Earnings (Estimated)4/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,500Year FoundedN/APrice Target and Rating Average Stock Price Forecast$31.20 High Stock Price Forecast$55.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+300.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-223,800,000.00 Net Margins-19.97% Pretax Margin-19.78% Return on Equity-7.57% Return on Assets-3.87% Debt Debt-to-Equity Ratio0.32 Current Ratio0.98 Quick Ratio0.70 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.35 Cash Flow$0.68 per share Price / Cash Flow11.41 Book Value$27.72 per share Price / Book0.28Miscellaneous Outstanding Shares50,140,000Free Float44,574,000Market Cap$390.59 million OptionableOptionable Beta0.94 Key ExecutivesRobert G. KramerPresident, Chief Executive Officer & DirectorAdam Robert HaveyChief Operating Officer & EVP-Business OperationsRichard Scott LindahlChief Financial Officer, Treasurer & Executive VPSharon M. SolomonChief Information Officer & Senior Vice PresidentChristopher H. CabellChief Medical Officer & Head-Clinical DevelopmentKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLIntercept PharmaceuticalsNASDAQ:ICPTXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 30,043 shares on 2/16/2023Ownership: 0.359%State of WyomingBought 4,281 shares on 2/16/2023Ownership: 0.021%Eagle Asset Management Inc.Sold 4,181 shares on 2/15/2023Ownership: 0.313%Squarepoint Ops LLCSold 3,771 shares on 2/15/2023Ownership: 0.021%Lazard Asset Management LLCBought 4,783 shares on 2/15/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions EBS Stock - Frequently Asked Questions Should I buy or sell Emergent BioSolutions stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks. What is Emergent BioSolutions' stock price forecast for 2023? 6 Wall Street research analysts have issued 12 month target prices for Emergent BioSolutions' stock. Their EBS share price forecasts range from $9.00 to $55.00. On average, they anticipate the company's stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 300.5% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts. How have EBS shares performed in 2023? Emergent BioSolutions' stock was trading at $11.81 on January 1st, 2023. Since then, EBS stock has decreased by 34.0% and is now trading at $7.79. View the best growth stocks for 2023 here. When is Emergent BioSolutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023. View our EBS earnings forecast. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings results on Monday, February, 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by $0.62. The biopharmaceutical company had revenue of $330.70 million for the quarter, compared to analysts' expectations of $298.23 million. Emergent BioSolutions had a negative net margin of 19.97% and a negative trailing twelve-month return on equity of 7.57%. The firm's quarterly revenue was down 54.3% on a year-over-year basis. During the same period in the previous year, the company earned $4.50 earnings per share. What ETFs hold Emergent BioSolutions' stock? ETFs with the largest weight of Emergent BioSolutions (NYSE:EBS) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco S&P SmallCap 600 Pure Value ETF (RZV), Cultivar ETF (CVAR), SPDR S&P Biotech ETF (XBI), ETFMG Treatments Testing and Advancements ETF (GERM), First Trust Small Cap Value AlphaDEX Fund (FYT), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco S&P SmallCap Health Care ETF (PSCH). What guidance has Emergent BioSolutions issued on next quarter's earnings? Emergent BioSolutions updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.18 billion. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV). What is Emergent BioSolutions' stock symbol? Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." Who are Emergent BioSolutions' major shareholders? Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (3.69%), Man Group plc (1.76%), Geode Capital Management LLC (1.72%), Charles Schwab Investment Management Inc. (1.39%), Morgan Stanley (1.31%) and AQR Capital Management LLC (1.10%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Emergent BioSolutions' stock price today? One share of EBS stock can currently be purchased for approximately $7.79. How much money does Emergent BioSolutions make? Emergent BioSolutions (NYSE:EBS) has a market capitalization of $390.59 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. How many employees does Emergent BioSolutions have? The company employs 2,500 workers across the globe. How can I contact Emergent BioSolutions? Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899. This page (NYSE:EBS) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.